Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia

Puccetti, Luca; Santilli, Francesca; Pasqui, Anna Laura; Lattanzio, Stefano; Liani, Rossella; Ciani, F.; Ferrante, Elisabetta; Ciabattoni, Giovanni; Scarpini, Francesca; Ghezzi, A.; Auteri, Alberto; Davı̀, Giovanni

doi:10.1016/j.atherosclerosis.2010.10.006

Cited by 79 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,22 A reduction of urinary isoprostanes or an increase of circulating vitamin E has been observed after short-term (3 days) or long-term treatment with statins. [23][24][25] In the present study, using 2 markers of oxidative stress, ie, urinary isoprostanes and sNOX2-dp, we demonstrated that high-dose atorvastatin acutely decreases both markers, indicating that it exerts a rapid antioxidant effect. The parallel decrease of Nox2 activity and urinary isoprostanes reinforces data from previous studies suggesting a major role for Nox2 in the production of isoprostanes.…”

Section: Antioxidant Effect By Statinsmentioning

confidence: 89%

Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2

et al. 2012

View full text Add to dashboard Cite

Background-Statins exert an antithrombotic effect in patients at risk of or with acute thrombosis, but no study has investigated whether this effect is immediate and whether there is an underline mechanism. Methods and Results-Patients with hypercholesterolemia were randomly allocated to a Mediterranean diet with low cholesterol intake (Ͻ300 mg/d; nϭ15) or atorvastatin (40 mg/d; nϭ15). Oxidative stress, as assessed by serum Nox2 and urinary isoprostanes, and platelet activation, as assessed by platelet recruitment, platelet isoprostanes, and thromboxane A 2 , platelet Nox2, Rac1, p47

show abstract

Section: Antioxidant Effect By Statinsmentioning

confidence: 89%

Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Of note, platelet formation of TxA 2 continued to decrease in parallel with LDL lowering, which is consistent with previous studies that showed a coincident reduction in platelet TxA 2 formation and serum LDL after prolonged statin treatment. 34 These findings led to a hypothesis of the existence of an early and late antiplatelet effect, which appears to be mediated by both lipid and lipid-lowering independent. The early antiplatelet effect appears to occur by NOX2 downregulation, with ensuing platelet isoprostane lowering, and by phospholipase A2 downregulation, with ensuing platelet TxA 2 formation reduction; these changes appear to be independent of lipid lowering, because no decrease in serum cholesterol was detected up to 24 hours after statin administration.…”

Section: Statins and Platelet Activationmentioning

confidence: 99%

Statins as Antithrombotic Drugs

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Thermally modified CRP promotes TXA2 production by platelets 97) . CRP is a predictor of urinary d-TXB2 in hypercholesterolemic patients given statins 98) . Therefore, CRP reduces the (PGI2＋PGI3)/TXA2 ratio, shifting the PGI/TXA balance towards the development and progression of cardiac disease and moving the regression line downwards (Fig.…”

Section: Relationship Between the (Pgi2＋pgi3)/txa2mentioning

confidence: 99%

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Ohnishi

Saitō

2013

JAT

View full text Add to dashboard Cite

The clinical efficacy of fish oil and high-purity eicosapentaenoic acid ethyl ester (hp-EPA-E) for treating cardiovascular disease (CVD) has been reported. Fish oil contains saturated and monounsaturated fatty acids that have pharmacological effects opposite to those of ω3 fatty acids (ω3). Moreover, ω3, such as EPA and docosahexaenoic acid (DHA), do not necessarily have the same metabolic and biological actions. This has obscured the clinical efficacy of ω3. Recently, the Japan EPA Lipid Intervention Study (JELIS) of hp-EPA-E established the clinical efficacy of EPA for CVD, and higher levels of blood EPA, not DHA, were found to be associated with a lower incidence of major coronary events. A significant reduction in the risk of coronary events was observed when the ratio of EPA to arachidonic acid (AA) (EPA/AA) was ＞0.75. Furthermore, the ratio of prostaglandin (

show abstract

Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia

Cited by 79 publications

References 26 publications

Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2

Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2

Statins as Antithrombotic Drugs

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Contact Info

Product

Resources

About